Literature DB >> 2686856

[In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha counties, Hainan Province].

C X Lan, X Lin, Z S Huang, Y S Chen, R N Guo.   

Abstract

Fifty-three cases of falciparum malaria in Linshui County, Baisha County and Sanya Municipality were treated with piperaquine phosphate at a total dose of 1.5g base over 3 days in July to December, 1986. The mean defervescence time was 36 +/- 20.7h; the mean asexual parasite clearance time was 69.7 +/- 20.9h. At 14-28d follow-up recrudescence was observed with asexual parasitemia in 7 of the 47 cases, showing RI resistance to piperaquine. Gametocytemia was positive in 35 cases (74.5%) during the follow-up period.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2686856

Source DB:  PubMed          Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi        ISSN： 1000-7423


  10 in total

Review 1.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  In Vitro Susceptibility of Plasmodium falciparum Isolates from the China-Myanmar Border Area to Piperaquine and Association with Candidate Markers.

Authors:  Yu Si; Weilin Zeng; Na Li; Chengqi Wang; Faiza Siddiqui; Jie Zhang; Liang Pi; Xi He; Luyi Zhao; Siqi Wang; Hui Zhao; Xinxin Li; Qi Yang; Jun Miao; Zhaoqing Yang; Liwang Cui
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

3.  Effects of a high-fat meal on the relative oral bioavailability of piperaquine.

Authors:  Ing-Kye Sim; Timothy M E Davis; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes.

Authors:  Mingming Hao; Dandan Jia; Qing Li; Yongshu He; Lili Yuan; Shuhui Xu; Kexuan Chen; Jia Wu; Lijuan Shen; Lin Sun; Hongbin Zhao; Zhaoqing Yang; Liwang Cui
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett; Harin Karunajeewa; Sean Hewitt; Mey Bouth Denis; Chiv Lim; Doung Socheat
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

6.  In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon.

Authors:  Leonardo K Basco; Pascal Ringwald
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

7.  Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.

Authors:  Rithea Leang; Walter R J Taylor; Denis Mey Bouth; Lijiang Song; Joel Tarning; Meng Chuor Char; Saorin Kim; Benoit Witkowski; Valentine Duru; Anais Domergue; Nimol Khim; Pascal Ringwald; Didier Menard
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

8.  Development of antimalarial drugs and their application in China: a historical review.

Authors:  Chang Chen
Journal:  Infect Dis Poverty       Date:  2014-03-20       Impact factor: 4.520

9.  Choreoathetosis - an unusual adverse effect of dihydroartemisinin-piperaquine: a case report.

Authors:  Benjamin Momo Kadia; Christian Morfaw; Armelle Corrine Gounoue Simo
Journal:  J Med Case Rep       Date:  2017-12-28

10.  Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.

Authors:  Badara Cisse; Matthew Cairns; Ernest Faye; Ousmane NDiaye; Babacar Faye; Cecile Cames; Yue Cheng; Maguette NDiaye; Aminata Collé Lô; Kirsten Simondon; Jean-Francois Trape; Oumar Faye; Jean Louis NDiaye; Oumar Gaye; Brian Greenwood; Paul Milligan
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.